

Determination of verapamil in pharmaceutical formulations using atomic emission spectrometry

Sabry Khalil ^{a,*}, Ahmed Kelzieh ^b

^a Department of Chemistry, Faculty of Science, Cairo University, Fayoum Branch, 63514 Fayoum, Egypt

^b Department of Chemistry, Faculty of Science, Tichreen University, Latakia, Riyadh 11491, Syria

Received 27 March 2001; received in revised form 9 May 2001; accepted 30 May 2001

Abstract

Ion-associate complexes of verapamil hydrochloride (VpCl) with (Cd(II), Co(II), Mn(II), and Zn(II)) thiocyanates, potassium ferricyanide, and ammonium reineckate are precipitated. The solubility of the solid complexes at the recommended optimum conditions of pH and ionic strength values have been studied. Saturated solutions of each ion associate at different temperatures under the optimum precipitation conditions were prepared and the metal ion contents in the supernatant were determined. The solubility products were thus calculated at different temperatures and the thermodynamic parameters ΔH , ΔG , and ΔS were calculated. A new accurate and precise method based on direct coupled plasma atomic emission spectrometry for the determination of VpCl ($1.96\text{--}62.86\ \mu\text{g ml}^{-1}$) in pure solutions and pharmaceutical preparations is given. © 2002 Elsevier Science B.V. All rights reserved.

Keywords: Atomic emission spectrometry; Verapamil; Ion-associate complexes; Pharmaceutical analysis

1. Introduction

Verapamil hydrochloride (VpCl), (5-[3,4-dimethoxyphen-ethyl) methylamino]-2-(3,4-dimethoxyphenyl)-2-isopropylvaleronitrile hydrochloride) [152-11-4; CAS 52-23-9] inhibits the transmembrane influx of calcium ions into the heart and vascular smooth muscle cells. It improves the relation between oxygen supply and consumption in the myocardium because oxygen

demand is lowered directly as a result of the effect on the energy consuming metabolic process of the myocardial cells and indirectly due to a reduction of the afterload.

It also enhances myocardial blood flow due to the calcium antagonistic effect on the smooth vascular muscles of coronaries. Therefore, it contributes to the anti-ischemic and anti-anginal efficiency in all types of coronary artery diseases and is also used as anti-hypertensive and anti-arrhythmic. Because of these pharmaceutical properties we found it important to prepare new ion associates containing verapamil and to study and elucidate their chemical structures to be applied to the analysis of VpCl.

* Corresponding author. Present address: Department of Chemistry, Teachers College at Riyadh, PO Box 4341, Riyadh 11491, Saudi Arabia. Tel.: +966-14963352; fax: +966-14915684.

E-mail address: s_khalil_99@yahoo.com (S. Khalil).

Several techniques have been used to determine VpCl including colorimetry [1,2], spectroflurometry [3], potentiometry [4,5], mass fragmentography [6], GC [7,8], HPLC [9–17], spectrophotometry [18,19] and other methods [20–27].

Although direct coupled plasma atomic emission spectrometry (DCP-AES) is a rapid method and has very low detection limits which cannot be reached by most of the above mentioned methods, it has not been applied yet to the determination of VpCl. The present work includes a new DCP-AES method for the determination of VpCl. The method is based on precipitation of the ion associates formed from the reaction of VpCl with $[\text{Cd}(\text{SCN})_4]^{2-}$, $[\text{Co}(\text{SCN})_4]^{2-}$, $[\text{Mn}(\text{SCN})_4]^{2-}$, $[\text{Zn}(\text{SCN})_4]^{2-}$, ammonium reineckate, $[\text{Cr}(\text{NH}_3)_2(\text{SCN})_4]^{-}$, or $[\text{Fe}(\text{CN})_6]^{3-}$. The metal ion content present in saturated solutions of these ion associates is determined employing DCP-AES and is used to calculate the concentration of VpCl.

DCP-AES is well suited for this type of determination because of its accuracy, precision, sensitivity, and freedom from interference.

2. Experimental

2.1. Reagents

Double-distilled water and analytical grade reagents were used to prepare all solutions. Verapamil HCl (ADWIC division of El-Nasr Pharmaceutical Chemicals Company, Cairo, Egypt), ammonium reineckate, potassium ferricyanide, zinc acetate and cobalt sulfate were Aldrich products, cadmium nitrate, manganese chloride (BDH) and Isoptin tablets containing 80 mg VpCl in coated sugar films were obtained from the Arab Drug Company (ADCO), Cairo, Egypt were used.

2.2. Apparatus

The pH of solutions was measured using an Orion (Cambridge, MA) digital pH meter. Direct current plasma AES for the determination

of metal ion is carried out using a Beckman Spectra Span III Emission spectrometer. Conductimetric measurements were carried out using YSI model 32M conductance meter with YSI 3417 dip type cell ($K_{\text{cell}} = 1$). The IR absorption spectra were obtained by applying the KBr disk technique using a PYE UNICAM SP-300 infrared spectrometer.

2.3. Preparation of ion associates

The ion associates were prepared by mixing solutions containing 1×10^{-3} mol of Cd(II), Co(II), Mn(II), or Zn(II) with a solution containing 4×10^{-3} mol of potassium thiocyanate and the requisite amount of VpCl. Potassium ferricyanide and ammonium reineckate 1×10^{-3} mol of the solution was mixed with the calculated amount of VpCl. The precipitates obtained were filtered, thoroughly washed with distilled water, and dried at room temperature. They were subjected to elemental microanalysis, infrared spectroscopy, nuclear magnetic resonance, and determination of the metal content.

2.4. Effect of pH on the solubility of ion associates

The choice of a suitable pH value at which the ion associates exhibit the lowest solubilities and the effect of pH on the degree of completeness of ion-associate formation were studied as follows: the solid ion associates were added to form saturated solutions in a series of solutions of different pH values ranging from 1 to 10; the pH value was adjusted with 0.1 M HCl or 0.1 M NaOH. The solutions were shaken for 4–6 h and left to stand for a week to attain a stable equilibrium. Then the saturated solution is filtered in a dry beaker (rejecting the first few milliliters of filtrate). One milliliter of the filtrate is transferred into a 100-ml measuring flask containing 1 ml of concentrated HNO_3 , and the volume is filled to the mark with distilled water. The equilibrium concentration of the metal ion present in the form of soluble inorganic complex ion is measured using DCP-AES, and hence the

solubility of the precipitate is evaluated, from which the solubility products of the ion associates were calculated.

2.5. Effect of ionic strength on the solubility of ion associates

A series of saturated solutions of the ion associate adjusted to the optimum pH value and having different ionic strength (0.1–1.0) was prepared using NaCl as the electrolyte. The same procedures as those used in the determination of the effect of pH have been followed to determine the optimum ionic strength values at which ion associates have the lowest solubilities.

2.6. Effect of temperature

The effect of temperature on the solubility of ion associates and the heat of the solution of ion associates were studied by preparing a suspension of the ion associate in solutions at the optimum pH and ionic strength values at different temperatures (25, 35, 45, and 60 °C). The metal ion content present in the form of soluble complex ion is measured using DCP-AES and the heat of the solution of the ion associates was determined applying the Van't Hoff isochore relation; thus

$$\log S = -\frac{\Delta H}{2.303RT} + \text{constant}, \quad (1)$$

where H is the heat of solution kJ mol^{-1} ; R is the universal gas constant, $8.3 \text{ J mol}^{-1} \text{ K}^{-1}$; and T is the absolute temperature in K. Thus, a plot of

$\log S$ against $1/T$ is a straight line with a slope equal to $(-\Delta H/2.303R)$ from which ΔH is calculated.

Gibb's free energy change (ΔG) and the entropy change (ΔS) are calculated using Eqs. (2) and (3), respectively,

$$\Delta G = -RT \ln K_{\text{sp}}, \quad (2)$$

where K_{sp} is the solubility product of ion associate and

$$\Delta G = \Delta H - T\Delta S. \quad (3)$$

2.7. Preparation of standard solutions

Standard solutions of divalent cadmium, cobalt, chromium, manganese, and zinc are prepared by weighing 1.0 g of a high-purity sample (cadmium shot, cobalt powder, chromium shot, manganese, and zinc metal, respectively), transferring it to a 1-l measuring flask and then adding 50 ml of concentrated HNO_3 . After dissolution the solution is diluted to 1 l with deionized water. The 1000-ppm solution is stored in a plastic bottle which has been presoaked in dilute HNO_3 . The solution is stable for approximately 1 year. Standard solution of iron was obtained from Aldrich.

2.8. Calibration of DCP-AES

Under the recommended conditions, calibration graphs were constructed of aqueous standards of Cd(II), Co(II), Cr(III), Mn(II), Zn(II) and Fe(III)

Table 1

Analytical parameters for the measurement of Cd, Co, Cr, Fe, Mn and Zn using DCP-AES

Element	Wavelength (nm)	Order	Plasma position	DL (mg l^{-1})	LDR (mg l^{-1})	BEC (mg)	RSD \times BEC (%)
Cd	214.43	105	0	0.005	0.05–300	0.4	1×1.0
Co	236.37	95	0	0.02	0.2–1000	0.8	1×0.7
Fe	248.30	90	0	0.01	0.1–1000	0.2	1×0.7
Cr	267.71	84	0	0.01	0.1–1000	0.4	7×0.7
Mn	257.61	87	0	0.003	0.03–100	0.1	1×0.1
Zn	206.20	109	0	0.01	0.1–1000	0.3	10×0.9

DL, detection limit; LDR, linear dynamic range; BEC, background equivalent concentration; RSD, relative standard deviation. For all elements—state, ion; entrance slits, $50 \times 300 \mu\text{m}^2$; exit slits, $100 \times 300 \mu\text{m}^2$.

Table 2
Elemental analysis, composition, and some physical properties of VpCl ion associates

Ion-associate composition	m.p. (°C)	Molar ratio	Color	% Found (calculated)				
				C	H	N	S	Metal
(C ₂₇ H ₃₉ N ₂ O ₄) ₂ [Cd(SCN) ₄]	205	2:1	White	55.26 (55.48)	6.05 (6.22)	8.72 (8.93)	10.11 (10.10)	8.74 (8.96)
(C ₂₇ H ₃₉ N ₂ O ₄) ₂ [Co(SCN) ₄]	186	2:1	Blue	57.56 (57.95)	6.32 (6.49)	9.12 (9.33)	10.44 (10.66)	4.83 (4.91)
(C ₂₇ H ₃₉ N ₂ O ₄) ₂ [Mn(SCN) ₄]	175	2:1	White	58.06 (58.15)	6.37 (6.52)	9.18 (9.36)	10.51 (10.69)	4.52 (4.59)
(C ₂₇ H ₃₉ N ₂ O ₄) ₂ [Zn(SCN) ₄]	136	2:1	White	57.52 (57.64)	6.28 (6.46)	9.13 (9.28)	10.46 (10.60)	5.25 (5.41)
(C ₂₇ H ₃₉ N ₂ O ₄)[Cr(NH ₃) ₂ (SCN) ₄]	194	1:1	Pink	48.03 (48.12)	5.66 (5.82)	14.36 (14.49)	16.38 (16.56)	6.62 (6.73)
(C ₂₇ H ₃₉ N ₂ O ₄) ₃ [Fe(CN) ₆]	223	3:1	Brown	66.08 (66.20)	7.34 (7.42)	10.49 (10.65)		3.34 (3.55)

in 1 M HNO₃ by performing triplicate measurements using solutions containing 0, 10, 20, and 50 ppm analyte concentrations as previously reported [28,29]. The calibration graphs are straight lines passing through the origin. The different parameters used for the measurement of Cd(II), Co(II), Cr(III), Mn(II), Zn(II) and Fe(III) are listed in Table 1.

2.9. Conductimetric measurements

The stoichiometry of the ion associates was elucidated by conductimetric titration of VpCl with the metal complex solutions.

2.10. Analytical determination of VpCl in aqueous solutions

Aliquots (0.1–3.2 ml) of 0.001 M VpCl solution are quantitatively transferred into 25-ml measuring flasks. To each flask 1.0 ml of 0.01 M standard solution of (Cd(II), Co(II), Mn(II), or Zn(II)) thiocyanate, ferricyanide, or ammonium reineckate is added and the flask is filled to the mark with the recommended buffer solution of the optimum pH and ionic strength values. The solutions are shaken well and left to stand for 15 min and then filtered through Whatman P/S paper (12.5 cm), and the equilibrium metal ion concentration in the filtrate is determined using DCP-AES. The metal ion consumed in the forma-

tion of ion associates is calculated, and the drug concentration is determined indirectly.

2.11. Analytical determination of VpCl in pharmaceutical preparations

The verapamil-containing pharmaceutical preparation (Isoptin tablets) 80 mg per tablet was successfully assayed using the present method. Sampling was made by grinding (12 tablets) and taking 0.62–1.307 mg/25 ml of the optimum condition solution and the tablets were analyzed applying the above-mentioned procedure.

3. Results and discussion

3.1. Composition and structure of ion associates

The results of elemental analysis (Table 2) of the produced solid ion associates reveal that two verapamilium cations form ion associates with one [M(SCN)₄]²⁻ and three [Fe(CN)₆]³⁻, while only one Vp combines with [Cr(NH₃)₂(SCN)₄]⁻ to form a 1:1 ion associate. These results are comparable to the previously reported results [28–31].

Conductimetric titrations of the investigated inorganic complexes with VpCl were performed to give insight into the stoichiometric compositions of the ion associates formed in solutions.

For all ion associates, the characteristic curves break at a molecular ratio ($[Vp]/[x]^{n-}$) of about 2, confirming the formation of 2:1 (Vp: x^{2-}) ion associates except in the case of the reineckate anion where the curve exhibits a sharp break at the 1:1 molecular ratio and in case of ferricyanide anion the curve exhibits a sharp break at the 3:1 molecular ratio. The results obtained coincide with the elemental analysis of the precipitated ion associate.

3.2. Effect of pH on the formation of ion associates

The choice of a suitable pH value at which the ion associate exhibits the lowest solubility (Table 3) is of prime importance in the use of such compounds in quantitative analysis. To determine this pH value, the solubility and the solubility products of the compounds are determined at 25 °C in solutions of varying pH

Table 3
Solubility and solubility product values of VpCl ion associates at optimum pH and 25 °C


Ion associate	pH	pS	pK_{sp}
$(Vp)_2[Cd(SCN)_4]$	6.0	2.96	8.27
$(Vp)_2[Co(SCN)_4]$	5.0	2.88	8.04
$(Vp)_2[Mn(SCN)_4]$	4.0	3.42	9.66
$(Vp)_2[Zn(SCN)_4]$	3.0	2.56	7.08
$(Vp)_3[Fe(CN)_6]$	3.0	2.23	7.48
$(Vp)[Cr(NH_3)_2(SCN)_4]$	2.0	4.15	8.30

pS, log solubility; pK_{sp} , log solubility product.

Table 4
Solubility and solubility product values at 25 °C of VpCl ion associates at their optimum pH and ionic strength (μ) values

Ion associate	pH	μ	pS	pK_{sp}
$(Vp)_2[Cd(SCN)_4]$	6.0	0.6	3.28	9.24
$(Vp)_2[Co(SCN)_4]$	5.0	0.3	3.23	9.11
$(Vp)_2[Mn(SCN)_4]$	4.0	0.2	3.57	10.13
$(Vp)_2[Zn(SCN)_4]$	3.0	0.4	3.14	8.82
$(Vp)_3[Fe(CN)_6]$	3.0	0.7	2.55	8.80
$(Vp)[Cr(NH_3)_2(SCN)_4]$	2.0	0.5	4.20	8.39

values. From the obtained results, it was observed that increasing the pH value of the medium decreases the solubility of the ion associate, although only slightly, until a certain pH value (Table 3), when it then increases again. This can be explained by considering the solubility equilibrium of the ion associate, e.g.



In acid medium, the hydrogen ion may react with the complex anion, $[M(SCN)_4]^{2-}$, while in basic medium, the hydroxyl ions may react with the verapamilium ion or the metal thiocyanate complexes. However, it is of note that the effect of pH is rather weak and the present method can be applied safely over a wide range of pH values.

3.3. Effect of ionic strength on the solubility of ion associates

The choice of a suitable μ value at which the ion associates exhibit the lowest solubility is also of prime importance in the use of such ion associates in quantitative analysis.

The solubility and the solubility product values of ion associates at different μ values (0.1–1.0) have been investigated at the optimum pH values. It was found that increasing the μ value of the medium decreases the solubility of the ion associates, probably due to the salting out effect, until the optimum μ value is reached (Table 4). It then increases again due to complexation reactions between the base cations and the concentrated NaCl in the medium that form the drug precipitate, and hence the concentration of the metal ion increases, leading to an increase in the calculated solubility values.

The values of the solubility and solubility product at the optimum conditions of pH and ionic strength (μ) are given in Table 4. The results indicate that the present ion associates are so sparingly soluble that VpCl can be determined accurately and precisely by the indirect method through precipitation of its ion associates with (Cd(II), Co(II), Mn(II), and Zn(II)) thiocyanate complexes, potassium ferricyanide and ammonium reineckate.

Table 5

Solubility (S), solubility product (K_{sp}), and some thermodynamic functions of verapamil ion associate at different temperatures

t (°C)	S (g mol l ⁻¹)	K_{sp}	ΔG (kJ mol ⁻¹)	ΔS (kJ mol ⁻¹)	ΔH (kJ mol ⁻¹)
<i>(Vp)₂[Cd(SCN)₄]</i>					
25	5.52×10^{-4}	5.68×10^{-10}	50.48	20.75	6.4×10^3
35	5.43×10^{-4}	6.40×10^{-10}	52.65	20.47	
45	6.28×10^{-4}	9.91×10^{-10}	53.73	19.83	
60	7.83×10^{-4}	1.92×10^{-9}	54.55	18.95	
<i>(Vp)₂[Zn(SCN)₄]</i>					
25	7.22×10^{-4}	1.51×10^{-9}	49.31	6.48	2.1×10^3
35	7.46×10^{-4}	1.66×10^{-9}	50.48	6.57	
45	7.92×10^{-4}	1.98×10^{-9}	52.66	5.96	
60	8.05×10^{-4}	2.09×10^{-9}	54.75	5.73	
<i>(Vp)₂[Mn(SCN)₄]</i>					
25	2.64×10^{-4}	7.35×10^{-11}	56.23	4.58	1.5×10^3
35	2.88×10^{-4}	9.55×10^{-11}	57.76	4.36	
45	2.97×10^{-4}	1.05×10^{-10}	59.65	4.43	
60	3.12×10^{-4}	1.21×10^{-10}	62.36	3.64	
<i>(Vp)₂[Co(SCN)₄]</i>					
25	5.78×10^{-4}	7.72×10^{-10}	51.16	6.97	2.4×10^3
35	5.96×10^{-4}	8.46×10^{-10}	52.42	6.54	
45	6.13×10^{-4}	9.21×10^{-10}	53.67	6.66	
60	6.48×10^{-4}	1.09×10^{-9}	56.25	6.23	
<i>(Vp)₃[Fe(CN)₆]</i>					
25	2.76×10^{-3}	1.57×10^{-9}	44.23	14.98	4.6×10^3
35	2.91×10^{-3}	1.94×10^{-9}	45.22	14.61	
45	3.25×10^{-3}	3.01×10^{-9}	46.16	13.46	
60	3.66×10^{-3}	4.84×10^{-9}	47.37	13.53	
<i>(Vp)[Cr(NH₃)₂(SCN)₄]</i>					
25	6.38×10^{-5}	4.07×10^{-9}	66.65	20.48	6.5×10^3
35	6.78×10^{-5}	4.60×10^{-9}	68.42	19.56	
45	7.45×10^{-5}	5.55×10^{-9}	70.33	18.37	
60	9.33×10^{-5}	8.70×10^{-9}	72.21	17.58	

3.4. Effect of temperature on the solubility of ion associates

The solubility of ion associates was investigated at different temperatures (25, 35, 45, and 60 °C) and the heat of solution (ΔH), Gibb's free energy change (ΔG), and the entropy change (ΔS) have been calculated (Table 5). The results show that VpCl is better determined at 25 °C than at higher temperatures, providing the optimum conditions of pH and ionic strength. This is because increasing temperature increases the solubility

where the process of dissolution of the precipitates is endothermic because the lattice energy is usually greater than the solvation energy and hence the stability of ion associates decreases. Gibb's free energy ΔG increases when the solubility of ion associates is decreased.

3.5. Analytical determination of VpCl in aqueous solutions and in Isoptin tablets

VpCl was determined precisely and accurately in aqueous solutions and in the pharmaceutical

Table 6
Analytical determination of VpCl in aqueous solution and in Isoptin tablets by DCP-AES

Sample	Amount taken (μg)	Mean recovery (%)	Mean RSD (%)
<i>[Cd(SCN)₄]²⁻</i>			
Pure VpCl solution	1.96–62.82	97.65	0.95
Isoptin tablets ^a	2.50–52.30	96.82	1.02
<i>[Co(SCN)₄]²⁻</i>			
Pure VpCl solution	1.96–62.82	97.66	1.34
Isoptin tablets ^a	2.50–52.30	96.78	1.16
<i>[Mn(SCN)₄]²⁻</i>			
Pure VpCl solution	1.96–62.82	99.85	1.10
Isoptin tablets ^a	2.50–52.30	99.26	1.21
<i>[Zn(SCN)₄]²⁻</i>			
Pure VpCl solution	1.96–62.82	98.87	1.03
Isoptin tablets ^a	2.50–52.30	97.75	1.23
<i>[Cr(NH₃)₂(SCN)₄]⁻</i>			
Pure VpCl solution	1.96–62.82	100.15	1.12
Isoptin tablets ^a	2.50–52.30	100.03	1.16
<i>[Fe(CN)₆]³⁻</i>			
Pure VpCl solution	1.96–62.82	97.62	1.32
Isoptin tablets ^a	2.50–52.30	96.58	1.28

RSD, relative standard deviation (five determinations).

^a ADCO, Cairo, Egypt.

Table 7
Linear regression analysis for VpCl using thiocyanates of (Cd, Co, Mn and Zn), ammonium reineckate and potassium ferricyanide

Parameters	Thiocyanates of				Ammonium reineckate	Potassium ferricyanide
	Cd	Co	Mn	Zn		
Optimum concentration range ($\mu\text{g ml}^{-1}$)	1.96–62.82	1.96–62.82	1.96–62.82	1.96–62.82	1.96–62.82	1.96–62.82
Shift or intercept of the regression line ^a	0.028	0.026	0.035	0.032	0.036	0.034
Slope of regression line	0.9976	0.9988	0.9965	1.0048	1.0072	1.0036
Student's/(2.310) ^b	2.11	2.15	2.08	2.10	2.03	2.06
Range of error (%)	99.8 \pm 1.3	99.7 \pm 1.5	99.6 \pm 1.4	100.0 \pm 1.6	100.0 \pm 1.2	100.0 \pm 1.3

^a Observed versus theoretical.

^b Tabulated 95% confidence limit (for slope).

preparation (Isoptin tablets) using the present method. The results given in (Table 6) reveal that for ammonium reineckate and $[\text{Mn}(\text{SCN})_4]^{2-}$ the recoveries are in the range 99.26–100.15%, reflecting a high accuracy which in addition to the high

precision indicated by very low values of relative standard deviations. For (Cd, Co, and Zn) thiocyanates and ferricyanide the recovery range is between 96.58 and 98.87% less accurate than that for ammonium reineckate and $[\text{Mn}(\text{SCN})_4]^{2-}$.

Generally, the present method's accuracy and precision are comparable to those of the British Pharmacopoeia methods [1,2]. Also, the present method is applicable over a wider concentration range than that of Issa et al. [19] where a 4.91–58.93 $\mu\text{g ml}^{-1}$ solution of VpCl can be determined.

In pharmaceutical analysis it is important to test the selectivity toward the excipients and the fillers added to the pharmaceutical preparations. Fortunately, such materials mostly do not interfere. This is clear from the results obtained for the pharmaceutical preparations (Table 6) that these excipients do not interfere.

Although the present method is more time consuming (22 min) in comparison to other methods such as (15 min for HPLC), it exhibits the advantages of simplicity, precision, higher sensitivity, accuracy and convenience. Moreover, the reproducibility of the results are superior to those obtained from other methods such as chromatography [8,12,13,16]. Therefore, the method should be useful for routine analytical and quality control assay of the investigated drug in dosage forms.

In order to establish whether the proposed method exhibits any fixed or proportional bias, a simple linear regression [32] of observed drug concentration against the theoretical values (five points) was calculated. Student's *t*-test [33] (at 95% confidence level) was applied to slope of the regression line (Table 7) and showed that it did not differ significantly from the ideal value of unity. Hence, it can be concluded that there are no systematic differences between the determination and true concentration over a wide range. The standard deviations can be considered satisfactory at least for the level of concentrations examined.

Although the present method is more time consuming than some other methods, it exhibits fair sensitivity and accuracy. Moreover, the reproducibility of the results is superior to that obtained from other methods.

References

- [1] The British Pharmacopoeia, Her Majesty's Stationary Office, London, vol. 2, 1988, p. 594.
- [2] The British Pharmacopoeia, Her Majesty's Stationary Office, London, vol. 2, 1988, p. 1017.
- [3] R.G. McAllister, S.M. Howell, *J. Pharm. Sci.* 65 (1976) 431–436.
- [4] The British Pharmacopoeia, Her Majesty's Stationary Office, London, 1980, Addendum, 1982, p. 121.
- [5] Z.L. Chang, *Analytical Profiles of Drug Substances*, 17,670, Academic Press, New York, 1988.
- [6] B. Spiegelhalter, M. Eichelbaum, *Arzneim. Forsch* 27 (1977) 94–99.
- [7] R.G. McAllister, T.G. Tan, D.W.A. Bourne, *J. Pharm. Sci.* 68 (1979) 574–581.
- [8] M. Ahnoff, B.A. Persson, *J. Chromatogr. Biomed. Appl.* 12 (1990) 181–213.
- [9] Proposed USP, 4588, The National Formulary, 1984.
- [10] S.A. Hamadi, S.L. Chang, P.J. Wadlund, *Anal. Lett.* 19 (1986) 1283–1297.
- [11] Y. Yazan, B. Bozan, *Pharmazie* 50 (1995) 117–119.
- [12] P. Hubert, J. Grommen, *J. Liq. Chromatogr.* 17 (1994) 2147–2170.
- [13] D.R. Rutledge, A.H. Abadi, L.M. Lopez, *J. Chromatogr. Sci.* 32 (1994) 153–156.
- [14] D. Romanova, E. Brondstetrova, D. Kralikova, L. Bozekova, M. Kriska, *Pharmazie* 49 (1994) 779–780.
- [15] P.M. Lacroxi, S.J. Graham, E.G. Lovering, *J. Pharm. Biomed. Anal.* 9 (1991) 817–822.
- [16] D.N. Sims, P.D. Felgate, H.E. Felgate, R.J. Lokan, *Forensic Sci. Int.* 49 (1991) 33–42.
- [17] Y. Oezkan, N. Yilmaz, S.A. Oezkan, I. Birylo, *Farmaco* 55 (2000) 376–382.
- [18] M.A.H. El-Sayed, M.H. Barary, M. Abdel-Salam, S.M. Mohamed, *Anal. Lett.* 22 (1989) 1665–1684.
- [19] Y.M. Issa, A.A. Salem, M.S. Bahbouh, *Anal. Lett.* 30 (1997) 1153–1166.
- [20] Y. Tekol, B. Goeguesten, *Arzneim. Forsch* 49 (1999) 673–678.
- [21] B. Heintz, A. Mueller, G. Lenhard, M. Schuetz, H.J. Hutt, *Arzneim. Forsch* 46 (1996) 1060–1063.
- [22] H. Thomas, M. Madeja, U. Musshoff, E. Speckmann, *Arzneim. Forsch* 47 (1997) 1–5.
- [23] R. Sandstr, H. Lennern, K. Hlen, A. Karlsson, *J. Pharm. Biomed. Anal.* 21 (1999) 43–49.
- [24] G. Li, X. Lin, C. Zhu, A. Hao, Y. Guan, *Analytica Chimica Acta* 421 (2000) 27–34.
- [25] P.R.P. Verma, R.K. Patel, *Pharm. Sci.* 2 (1996) 6269–6274.
- [26] G. Froehlich, S. Burmeister, A. Wiedemann, M. Bulitta, *Arzneim. Forsch* 48 (1998) 5486–5491.
- [27] M. Rahman, C.A. Lau-Cam, *Pharmazie* 54 (1999) 2132–2136.
- [28] S. Khalil, *J. Pharm. Biomed. Anal.* 21 (1999) 697–702.
- [29] S. Khalil, *Mikrochim. Acta* 130 (1999) 181–184.

- [30] S. Khalil, M.M. El-Rabiehi, *J. Pharm. Biomed. Anal.* 22 (1) (2000) 7–12.
- [31] S. Khalil, N. Borham, *J. Pharm. Biomed. Anal.* 22 (2) (2000) 235–240.
- [32] J.C. Miller, J.N. Miller, *Statistics for Analytical Chemistry*, Ellis Horwood, Chichester, 1984, p. 90.
- [33] J.C. Miller, J.N. Miller, *Statistics for Analytical Chemistry*, second ed., Ellis Horwood, Chichester, 1988.